Trinity Biotech plc (NASDAQ:TRIB) Sees Significant Growth in Short Interest

Trinity Biotech plc (NASDAQ:TRIB) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 58,400 shares, a growth of 100.7% from the December 31st total of 29,100 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily trading volume, of 190,700 shares, the short-interest ratio is presently 0.3 days.

Trinity Biotech Stock Down 2.7 %

Shares of NASDAQ TRIB traded down $0.03 during mid-day trading on Friday, hitting $0.90. 439,015 shares of the company were exchanged, compared to its average volume of 6,336,626. The stock has a 50 day simple moving average of $0.93 and a 200-day simple moving average of $1.61. Trinity Biotech has a 1-year low of $0.74 and a 1-year high of $3.55. The firm has a market cap of $10.06 million, a price-to-earnings ratio of -0.40 and a beta of 1.01.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Trinity Biotech in a report on Wednesday. They set a “hold” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC grew its holdings in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent quarter. 78.97% of the stock is currently owned by institutional investors.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.